ERIBULIN MESYLATE

Search structure
Trade Names:
Synonyms:
Status: Approved (2010)
Entry Type: Small molecule
Molecule Category: Salt
UNII: AV9U0660CW
Parent Compound: ERIBULIN

Structure
InChI Key QAMYWGZHLCQOOJ-WRNBYXCMSA-N
Smile C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@H]3[C@H](C[C@H]4O[C@@H](CC[C@@H]1O2)C[C@@H](C)C4=C)O[C@H](C[C@H](O)CN)[C@@H]3OC.CS(=O)(=O)O
InChI
InChI=1S/C40H59NO11.CH4O3S/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41;1-5(2,3)4/h19,23-39,43H,2-3,5-18,41H2,1,4H3;1H3,(H,2,3,4)/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+;/m1./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C41H63NO14S
Molecular Weight 826.01
AlogP 3.44
Hydrogen Bond Acceptor 12.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 4.0
Polar Surface Area 146.39
Molecular species BASE
Aromatic Rings 0.0
Heavy Atoms 52.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Tubulin inhibitor PubMed DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Breast Neoplasms 4 D001943 ClinicalTrials
Breast Neoplasms 4 D001943 ClinicalTrials
Breast Neoplasms 4 D001943 ClinicalTrials
Urethral Neoplasms 3 D014523 ClinicalTrials
Sarcoma 3 D012509 ClinicalTrials
Salivary Gland Neoplasms 2 D012468 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 2 D002289 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 2 D064129 ClinicalTrials
Osteosarcoma 2 D012516 ClinicalTrials
Head and Neck Neoplasms 2 D006258 ClinicalTrials
Breast Neoplasms, Male 2 D018567 ClinicalTrials
Prostatic Neoplasms 2 D011471 ClinicalTrials
Triple Negative Breast Neoplasms 2 D064726 ClinicalTrials
Uterine Cervical Neoplasms 2 D002583 ClinicalTrials
Urinary Bladder Neoplasms 1 D001749 ClinicalTrials
Lymphoma 1 D008223 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials
Brain Neoplasms 0 D001932 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Blood and lymphatic system disorders
19.99
General disorders and administration site conditions
14.62
Respiratory, thoracic and mediastinal disorders
8.85
Gastrointestinal disorders
7.85
Nervous system disorders
6.64
Infections and infestations
5.87
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
4.7
Vascular disorders
4.21
Metabolism and nutrition disorders
3.66
Investigations
3.65
Cardiac disorders
3.24
Skin and subcutaneous tissue disorders
3.17
Immune system disorders
2.78
Musculoskeletal and connective tissue disorders
2.48

Cross References

Resources Reference
ChEBI 70710
ChEMBL CHEMBL1683544
FDA SRS AV9U0660CW
PubChem 17755248
CONTENTS